<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01526369</url>
  </required_header>
  <id_info>
    <org_study_id>CTRIAL-IE (ICORG) 11-10</org_study_id>
    <nct_id>NCT01526369</nct_id>
  </id_info>
  <brief_title>A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer</brief_title>
  <acronym>TH V THL</acronym>
  <official_title>A Phase III Randomized Study of TH (Paclitaxel and Trastuzumab) Versus THL (Paclitaxel, Trastuzumab and Lapatinib) in First Line Treatment of HER2-positive Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Trials Ireland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cancer Trials Ireland</source>
  <brief_summary>
    <textblock>
      The proposed phase III randomised trial will compare the efficacy of trastuzumab and
      paclitaxel with trastuzumab, paclitaxel and lapatinib in first line treatment of HER2
      positive metastatic breast cancer. The investigators will also examine potential predictive
      biomarkers of response to trastuzumab and lapatinib in pre-treatment biopsy samples and serum
      samples.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Paclitaxel and Trastuzumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Weekly paclitaxel (80mg/m², for 3 weeks of a 4 week cycle) + trastuzumab (8mg/kg loading dose on cycle 1 day 1 and 4mg/kg every 2 weeks) until disease progression, unacceptable toxicity or consent withdrawal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel, Trastuzumab and Lapatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly paclitaxel (80 mg/m², for 3 weeks of a 4 week cycle) + trastuzumab (8 mg/kg loading dose on cycle 1 day 1 and 4 mg/kg every 2 weeks)
+ lapatinib (1,000 mg daily), until disease progression, unacceptable toxicity or consent withdrawal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <arm_group_label>Paclitaxel and Trastuzumab</arm_group_label>
    <arm_group_label>Paclitaxel, Trastuzumab and Lapatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>Paclitaxel and Trastuzumab</arm_group_label>
    <arm_group_label>Paclitaxel, Trastuzumab and Lapatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapatinib</intervention_name>
    <arm_group_label>Paclitaxel, Trastuzumab and Lapatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent obtained prior to any study-related procedures

          2. Female age 18 years or greater.

          3. ECOG Performance Status of 0 or 1.

          4. Histologically or cytologically-confirmed invasive metastatic breast cancer.

          5. Patients must have measurable disease according to RECIST criteria Version 1.1,
             defined as at least one lesion that can be accurately measured in at least one
             dimension (longest diameter to be recorded for non-nodal lesions and short axis for
             nodal lesions) as &gt;20 mm with conventional techniques or as &gt;10 mm with spiral CT
             scan,MRI, or calipers by clinical exam.

          6. Tumour shows HER2 over-expression (3+ by IHC and/or FISH + ) by testing of the primary
             tumour and if available the biopsied metastatic lesion

          7. Patients who received prior radiotherapy must have completed it at least 4 weeks
             before registration and recovered from all treatment-related toxicities.

          8. Cardiac ejection fraction within the institutional range of normal as measured by MUGA
             or ECHO within 14 days prior to registration. Note that baseline and on treatment
             scans should be performed using the same modality and preferably at the same
             institution.

          9. Adequate haematological, hepatic, and renal function.

               -  Haemoglobin ≥ 9g/dL

               -  Neutrophils (ANC/AGC) ≥1500/mm³ (1.5 x 10^9/L)

               -  Platelets ≥ (100 x 10^9/L)

               -  Total bilirubin ≤ 1.5mg/dL (25.65 μmol/L)

               -  Both ALT (SGPT) and AST (SGOT) ≤ 3 x ULN with or without liver Metastasis

               -  Alkaline phosphatase ≤ 2.5 x ULN

               -  Serum creatinine ≤1.5 ULN or calculated creatinine clearance (CrCl) ≥ 30mL/min
                  according to the Cockcroft and Gault formula (Appendix K)

         10. Able to swallow and retain oral medication.

         11. Women of child-bearing potential must agree to use adequate contraception (hormonal or
             barrier method of birth control or abstinence) prior to study entry and for the
             duration of study participation. Female patients of childbearing potential must have
             pregnancy excluded by urine or serum beta-HCG testing within 7 days prior to
             registration.

         12. Estimated life expectancy greater than 12 weeks

        Exclusion Criteria:

          1. Prior systemic therapy for metastatic disease (except one line of hormonal therapy for
             metastatic disease without trastuzumab).

          2. Recurrence within 12 months from completion of adjuvant chemotherapy to the
             development of metastatic disease.

          3. Recurrence within 6 months from completion of adjuvant trastuzumab to the development
             of metastatic disease.

          4. Prior lapatinib treatment.

          5. Peripheral neuropathy ≥ grade 2

          6. Patients with known CNS metastasis should be excluded from this clinical trial

          7. Prior radiotherapy to more than half of the bony pelvis.

          8. Uncontrolled or symptomatic angina, uncontrolled arrhythmias, congestive heart
             failure, a documented MI within 6 months prior to registration or any other cardiac
             disorders, which in the opinion of the treating physician, would make this protocol
             unreasonably hazardous for the patient .

          9. Immediate or delayed hypersensitivity or untoward reaction to paclitaxel, trastuzumab,
             or other related compounds, or to drugs chemically related to lapatinib (including
             other anilinoquinazolines, e.g. gefitinib (Iressa®) and erlotinib (Tarceva®), or other
             chemically-related compounds).

         10. Pregnant or breastfeeding women are excluded from this study.

         11. Patients should not be receiving any other investigational agents (within 30 days
             prior to registration) or receiving concurrent anticancer therapy.

         12. Concomitant requirement for medication classified as CYP3A4 inducers or inhibitors
             (Table 9).

         13. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, or psychiatric illness/social situations that would limit compliance with
             study requirements.

         14. Patients with GI tract disease resulting in an inability to take oral medication,
             malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures
             affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative
             colitis).

         15. Have current active hepatic or biliary disease (with exception of patients with
             Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver
             disease per investigator assessment)

         16. Concurrent treatment with ovarian hormone replacement therapy. Prior treatment must be
             stopped prior to registration.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Helsinki University Hopsital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuopio University hospital</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRLC Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interdisziplinäre Onkologische Zentrum München (IOZ München)</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <state>Leinster</state>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Private Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St James's Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Galway</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwestern Regional Hospital</name>
      <address>
        <city>Limerick</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sligo General Hospital</name>
      <address>
        <city>Sligo</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waterford Regional Hospital</name>
      <address>
        <city>Waterford</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo University Hopsital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Maria</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaen</name>
      <address>
        <city>Andalucia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra Senora de Sonsoles</name>
      <address>
        <city>Avila</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Cristina</name>
      <address>
        <city>Badajoz</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>Canarias</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova de Lleida</name>
      <address>
        <city>Cataluna</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Luz</name>
      <address>
        <city>Cuenca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico de Galicia</name>
      <address>
        <city>Galicia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Grannollers</name>
      <address>
        <city>Granollers</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Xeral Calde / Hospital Lucus Augusti</name>
      <address>
        <city>Lugo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Mataro</name>
      <address>
        <city>Mataro</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Donostia</name>
      <address>
        <city>Pais Vasco</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Cristina</name>
      <address>
        <city>Parla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario 'Lozano Blesa'</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2012</study_first_submitted>
  <study_first_submitted_qc>February 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2012</study_first_posted>
  <last_update_submitted>May 30, 2017</last_update_submitted>
  <last_update_submitted_qc>May 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2-positive metastatic breast cancer.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

